M6A reduction relieves FUS-associated ALS granules
- PMID: 38866783
- PMCID: PMC11169559
- DOI: 10.1038/s41467-024-49416-5
M6A reduction relieves FUS-associated ALS granules
Abstract
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease due to gradual motoneurons (MN) degeneration. Among the processes associated to ALS pathogenesis, there is the formation of cytoplasmic inclusions produced by aggregation of mutant proteins, among which the RNA binding protein FUS. Here we show that, in neuronal cells and in iPSC-derived MN expressing mutant FUS, such inclusions are significantly reduced in number and dissolve faster when the RNA m6A content is diminished. Interestingly, stress granules formed in ALS conditions showed a distinctive transcriptome with respect to control cells, which reverted to similar to control after m6A downregulation. Notably, cells expressing mutant FUS were characterized by higher m6A levels suggesting a possible link between m6A homeostasis and pathological aggregates. Finally, we show that FUS inclusions are reduced also in patient-derived fibroblasts treated with STM-2457, an inhibitor of METTL3 activity, paving the way for its possible use for counteracting aggregate formation in ALS.
© 2024. The Author(s).
Conflict of interest statement
Sapienza University of Rome, Fondazione Istituto Italiano di Tecnologia (IIT) are currently in the process of a patent application. Patent applicant: Sapienza University of Rome, Fondazione Istituto Italiano di Tecnologia (IIT) name of inventors: Irene Bozzoni, Gaia Di Timoteo, Andrea Giuliani, Adriano Setti application number: IT102023000022302 status of application: pending specific aspect of manuscript covered in patent application: use of METTL3 inhibitors in the treatment of protein aggregation diseases. The remaining authors declared no competing interests.
Figures




References
-
- Blair, H. A. Tofersen: first approval. Drugs83, 1039 (2023). - PubMed
MeSH terms
Substances
Grants and funding
- ERC-2019-SyG 855923-ASTRA/EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council)
- ERC-2018-CoG 818669-BrightEyes/EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council)
- AIRC IG 2019 Id. 23053/Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)
- PRIN 2017 2017P352Z4/Ministero dell'Istruzione, dell'Università e della Ricerca (Ministry of Education, University and Research)
- NextGenerationEU PNRR MUR/Ministero dell'Istruzione, dell'Università e della Ricerca (Ministry of Education, University and Research)
- "National Center for Gene Therapy and Drugbased on RNA Technology" (CN00000041)/Ministero dell'Istruzione, dell'Università e della Ricerca (Ministry of Education, University and Research)
- "National Center for Gene Therapy and Drug based on RNA Technology" (CN00000041)/Ministero dell'Istruzione, dell'Università e della Ricerca (Ministry of Education, University and Research)
- NextGenerationEU PNRR MUR/Ministero dell'Istruzione, dell'Università e della Ricerca (Ministry of Education, University and Research)
- "Sapienza" Ateneo Project 2021 n. RM12117A61C811CE/Sapienza Università di Roma (Sapienza University of Rome)
- Regione Lazio PROGETTI DI GRUPPI DI RICERCA 2020 - A0375-2020-36597/Regione Lazio (Region of Lazio)
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous